SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 7/26/2017 7:23:45 PM - Followers: 147 - Board type: Free - Posts Today: 15

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#4884  Sticky Note AUPH: Now that Ph3 for LN is underway Lunacy aka John Galt 07/19/17 06:05:27 PM
#5000   AUPH- we get four pumps from Motley Fool, biotech_researcher 07/26/17 07:23:45 PM
#4999   The sky may fall. Isn't even scarier than grandma_of_jbraika 07/26/17 04:02:28 PM
#4998   Those government numbers are wrong (no surprise) moosedogger 07/26/17 02:02:21 PM
#4997   You may be confused. That was from the biotech_researcher 07/26/17 12:31:13 PM
#4996   so you are saying a drug in the cervelo 07/26/17 12:15:22 PM
#4995   45 sites https://clinicaltrials.gov/ct2/show/NCT03021499?term=Voclosporin&rank=3 LivingTheDream 07/26/17 12:11:59 PM
#4994   Welcome, if you have extra time read thru Lunacy aka John Galt 07/26/17 11:16:18 AM
#4993   Link: https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm biotech_researcher 07/26/17 11:15:32 AM
#4992   Important document from the FDA's web site that biotech_researcher 07/26/17 11:14:27 AM
#4991   we are blind to the results until the end zzaatt 07/26/17 11:00:18 AM
#4986   I'm in at $2.40 and $3.70. Selling in Foxxycleopatra 07/26/17 03:10:28 AM
#4985   "$11 to $12 is about right" I SantaFe Miguel 07/25/17 09:39:16 PM
#4984   "I see the 12 months projection on yahoo biotech_researcher 07/25/17 08:48:37 PM
#4983   New to the board. Found out about ducruacuteo11 07/25/17 06:44:15 PM
#4980   https://www.fool.com/investing/2017/07/25/aspreva-pharmaceuticals-new-drug-clini Lunacy aka John Galt 07/25/17 03:15:58 PM
#4979   Eddie, I'm up close to 40% in 10 SantaFe Miguel 07/25/17 01:51:09 PM
#4978   SvsB, all valid points. Thank you.. biotech_researcher 07/25/17 12:18:26 PM
#4977   Well, we are up 300% since the year SvsB 07/25/17 12:08:20 PM
#4975   Well, we are down over $1.00 from a biotech_researcher 07/25/17 10:55:22 AM
#4974   starting to look like a generic orphan drug cervelo 07/25/17 09:45:37 AM
#4972   Foxxy -- I'm sure you agree that Aurinia SantaFe Miguel 07/24/17 11:43:17 PM
#4971   Thx Jesspro, for the heads up. northern vortex 07/24/17 11:30:05 PM
#4970   After Kramer it rocketed up to about 7.70 Foxxycleopatra 07/24/17 06:16:23 PM
#4969   I Love losing money here TinyGreenSprout 07/24/17 01:21:52 PM
#4968   Nsomyak, just google those two words and you'll Jesspro 07/24/17 11:27:37 AM
#4967   No worries, awlau. Glickman covered everyone's butt Zeppo 07/24/17 10:33:46 AM
#4966   that is a speculative comment cervelo 07/24/17 10:24:01 AM
#4965   It has been straight down since Cramer..... biotech_researcher 07/24/17 10:09:54 AM
#4964   Looks like Vid's wish for the 5's has Maciste 07/24/17 10:04:57 AM
#4963   "......thanks for the testimonials on your link." moosedogger 07/24/17 09:26:49 AM
#4956   Northern Vortex, there is also a discussion of Jesspro 07/23/17 06:45:59 PM
#4955   In my estimation, Richard Glickman conducted the Cramer northern vortex 07/23/17 05:16:52 PM
#4950   CellCept is NOT a chemotherapy agent: https://www.drugs.com/cellcept.html biotech_researcher 07/22/17 08:25:46 PM
#4949   So Cellcept is not a chemotherapy agent. Wow! Jesspro 07/22/17 05:53:07 PM
#4944   ILJIN has been being the absolutely #1 AUPH grandma_of_jbraika 07/22/17 08:47:43 AM
#4942   Thanks to all for the informative Posts. I tiv111 07/22/17 08:30:46 AM
#4941   can't resist adding: moosedogger 07/22/17 08:20:20 AM
#4940   "It ain't what you don't know that gets moosedogger 07/22/17 08:02:31 AM
#4938   That is even better news, thanks moose! biotech_researcher 07/22/17 07:45:27 AM
#4937   "There is a misconception that CellCept is a moosedogger 07/22/17 07:37:32 AM
#4936   SvsB, that was a heart wrenching story, and biotech_researcher 07/22/17 07:07:39 AM
#4935   Your concern for patients undergoing radical treatments for SantaFe Miguel 07/21/17 11:35:50 PM
#4934   I just asked (at dinner tonight) my best SvsB 07/21/17 11:30:57 PM
#4933   Today is cellcept, Next week or month, we'll Jesspro 07/21/17 11:27:59 PM
#4932   Which sounds better to you, taking CellCept or Lunacy aka John Galt 07/21/17 10:46:11 PM
#4931   As I said, ask people that have biotech_researcher 07/21/17 10:33:50 PM
#4930   Unless it saves your life though, right? Lunacy aka John Galt 07/21/17 10:29:20 PM
#4929   Make fun of me all you want, but biotech_researcher 07/21/17 10:27:36 PM
#4928   We all know that finding a cure for Lunacy aka John Galt 07/21/17 06:12:25 PM
#4927   The only disappointing thing is that the combination biotech_researcher 07/21/17 03:47:21 PM
PostSubject